Do analysts rate MIRA or ENLV?

Enlivex Therapeutics has a consensus price target of $16.50, indicating a potential upside of 2,298.26%. Given Enlivex Therapeutics' higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Enlivex Therapeutics 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, MIRA or ENLV?

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A Enlivex Therapeutics N/A N/A $1.24B -$0.55 N/A

Is MIRA or ENLV more profitable?

Enlivex Therapeutics' return on equity of 248.08% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -140.82% -135.01% Enlivex Therapeutics N/A 248.08% 206.39%

Do analysts prefer GALT or MIRA?

Galectin Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 298.55%. Given Galectin Therapeutics' higher probable upside, equities analysts plainly believe Galectin Therapeutics is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Galectin Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has better earnings & valuation, GALT or MIRA?

Galectin Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Galectin Therapeutics N/A N/A -$30.84M -$0.41 N/A MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A

Is GALT or MIRA more profitable?

Galectin Therapeutics' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Galectin Therapeutics N/A N/A -164.69% MIRA Pharmaceuticals N/A -140.82% -135.01%

Do analysts rate MIRA or ABOS?

Acumen Pharmaceuticals has a consensus target price of $6.67, suggesting a potential upside of 178.36%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Acumen Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has preferable earnings & valuation, MIRA or ABOS?

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A

Is MIRA or ABOS more profitable?

Acumen Pharmaceuticals' return on equity of -123.07% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -140.82% -135.01% Acumen Pharmaceuticals N/A -123.07% -79.41%

Do analysts prefer MIRA or MOLN?

Molecular Partners has a consensus target price of $8.38, suggesting a potential upside of 112.56%. Given Molecular Partners' stronger consensus rating and higher probable upside, analysts plainly believe Molecular Partners is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Molecular Partners 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has stronger earnings & valuation, MIRA or MOLN?

Molecular Partners is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MIRA Pharmaceuticals N/A N/A -$10.44M -$1.30 N/A Molecular Partners N/A N/A -$74.41M -$1.94 N/A

Is MIRA or MOLN more profitable?

Molecular Partners' return on equity of -66.62% beat MIRA Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets MIRA Pharmaceuticals N/A -140.82% -135.01% Molecular Partners N/A -66.62% -54.85%

MIRA Pharmaceuticals (MIRA) Competitors

$0.97 +0.03 (+3.40%)

As of 10:18 AM Eastern

Compare

MIRA vs. ENLV, GALT, ABOS, PLX, and MOLN

Should you buy MIRA Pharmaceuticals stock or one of its competitors? MarketBeat compares MIRA Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MIRA Pharmaceuticals include Enlivex Therapeutics (ENLV), Galectin Therapeutics (GALT), Acumen Pharmaceuticals (ABOS), Protalix BioTherapeutics (PLX), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry.

How does MIRA Pharmaceuticals compare to Enlivex Therapeutics?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

Enlivex Therapeutics' return on equity of 248.08% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Enlivex Therapeutics	N/A	248.08%	206.39%

In the previous week, Enlivex Therapeutics had 2 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 3 mentions for Enlivex Therapeutics and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.94 beat Enlivex Therapeutics' score of 0.93 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Positive
Enlivex Therapeutics	Positive

Enlivex Therapeutics has a consensus price target of $16.50, indicating a potential upside of 2,298.26%. Given Enlivex Therapeutics' higher probable upside, analysts clearly believe Enlivex Therapeutics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Enlivex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Enlivex Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Enlivex Therapeutics	N/A	N/A	$1.24B	-$0.55	N/A

35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

MIRA Pharmaceuticals has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Enlivex Therapeutics has a beta of 1.47, meaning that its stock price is 47% more volatile than the broader market.

Summary

Enlivex Therapeutics beats MIRA Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Galectin Therapeutics?

Galectin Therapeutics (NASDAQ:GALT) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Galectin Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 298.55%. Given Galectin Therapeutics' higher probable upside, equities analysts plainly believe Galectin Therapeutics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Galectin Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Galectin Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market.

Galectin Therapeutics is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Galectin Therapeutics	N/A	N/A	-$30.84M	-$0.41	N/A
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

Galectin Therapeutics' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Galectin Therapeutics	N/A	N/A	-164.69%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

11.7% of Galectin Therapeutics shares are held by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. 52.6% of Galectin Therapeutics shares are held by company insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Galectin Therapeutics had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Galectin Therapeutics and 1 mentions for MIRA Pharmaceuticals. Galectin Therapeutics' average media sentiment score of 0.94 equaled MIRA Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Galectin Therapeutics	Positive
MIRA Pharmaceuticals	Positive

Summary

Galectin Therapeutics and MIRA Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Acumen Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Acumen Pharmaceuticals is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A

MIRA Pharmaceuticals has a beta of 1.43, meaning that its stock price is 43% more volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.34, meaning that its stock price is 66% less volatile than the broader market.

Acumen Pharmaceuticals' return on equity of -123.07% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%

In the previous week, Acumen Pharmaceuticals had 3 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 4 mentions for Acumen Pharmaceuticals and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.94 beat Acumen Pharmaceuticals' score of 0.59 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Positive
Acumen Pharmaceuticals	Positive

Acumen Pharmaceuticals has a consensus target price of $6.67, suggesting a potential upside of 178.36%. Given Acumen Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Acumen Pharmaceuticals is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 10.2% of Acumen Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Acumen Pharmaceuticals beats MIRA Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Protalix BioTherapeutics?

Protalix BioTherapeutics (NYSE:PLX) and MIRA Pharmaceuticals (NASDAQ:MIRA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, media sentiment, risk, institutional ownership, profitability and analyst recommendations.

Protalix BioTherapeutics has a beta of -0.02, suggesting that its stock price is 102% less volatile than the broader market. Comparatively, MIRA Pharmaceuticals has a beta of 1.43, suggesting that its stock price is 43% more volatile than the broader market.

Protalix BioTherapeutics currently has a consensus price target of $12.00, indicating a potential upside of 470.07%. Given Protalix BioTherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Protalix BioTherapeutics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Protalix BioTherapeutics has higher revenue and earnings than MIRA Pharmaceuticals. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protalix BioTherapeutics	$76.38M	2.22	$8.31M	$0.18	11.69
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A

MIRA Pharmaceuticals has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Protalix BioTherapeutics' return on equity of -30.89% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%

In the previous week, MIRA Pharmaceuticals had 1 more articles in the media than Protalix BioTherapeutics. MarketBeat recorded 1 mentions for MIRA Pharmaceuticals and 0 mentions for Protalix BioTherapeutics. MIRA Pharmaceuticals' average media sentiment score of 0.94 beat Protalix BioTherapeutics' score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Protalix BioTherapeutics	Neutral
MIRA Pharmaceuticals	Positive

16.5% of Protalix BioTherapeutics shares are owned by institutional investors. Comparatively, 35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. 6.5% of Protalix BioTherapeutics shares are owned by insiders. Comparatively, 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Protalix BioTherapeutics and MIRA Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does MIRA Pharmaceuticals compare to Molecular Partners?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

MIRA Pharmaceuticals has a beta of 1.43, indicating that its stock price is 43% more volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Molecular Partners is trading at a lower price-to-earnings ratio than MIRA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Molecular Partners	N/A	N/A	-$74.41M	-$1.94	N/A

Molecular Partners' return on equity of -66.62% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Molecular Partners	N/A	-66.62%	-54.85%

In the previous week, Molecular Partners had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 2 mentions for Molecular Partners and 1 mentions for MIRA Pharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.94 beat Molecular Partners' score of 0.44 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Positive
Molecular Partners	Neutral

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.5% of Molecular Partners shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 5.9% of Molecular Partners shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Molecular Partners has a consensus target price of $8.38, suggesting a potential upside of 112.56%. Given Molecular Partners' stronger consensus rating and higher probable upside, analysts plainly believe Molecular Partners is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

MIRA Pharmaceuticals beats Molecular Partners on 7 of the 13 factors compared between the two stocks.

Get MIRA Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIRA vs. The Competition

Export

Metric	MIRA Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$41.10M	$3.39B	$6.49B	$12.31B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	-0.75	20.05	24.05	24.76
Price / Sales	N/A	325.48	542.61	168.32
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	3.89	8.16	10.69	6.90
Net Income	-$10.44M	$23.89M	$3.57B	$337.45M
7 Day Performance	-2.80%	3.66%	1.56%	2.84%
1 Month Performance	0.93%	1.69%	2.49%	4.78%
1 Year Performance	-19.67%	46.95%	26.51%	33.08%

MIRA Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIRA MIRA Pharmaceuticals	0.9624 of 5 stars	$0.97 +3.4%	N/A	-22.3%	$41.10M	N/A	N/A	2	Gap Up
ENLV Enlivex Therapeutics	2.4469 of 5 stars	$0.70 -2.5%	$16.50 +2,270.7%	-26.0%	$165.22M	N/A	N/A	70	News Coverage Gap Up
GALT Galectin Therapeutics	1.8129 of 5 stars	$2.45 +2.1%	$11.00 +349.0%	+94.9%	$161.35M	N/A	N/A	9	Analyst Upgrade
ABOS Acumen Pharmaceuticals	2.5307 of 5 stars	$2.23 +2.7%	$6.67 +199.1%	+121.5%	$161.07M	N/A	N/A	20	Positive News Analyst Downgrade
PLX Protalix BioTherapeutics	2.7689 of 5 stars	$2.00 +1.8%	$12.00 +501.5%	+40.3%	$160.74M	$76.38M	N/A	200

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIRA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. ENLV, GALT, ABOS, PLX, and MOLN

How does MIRA Pharmaceuticals compare to Enlivex Therapeutics?

Summary

How does MIRA Pharmaceuticals compare to Galectin Therapeutics?

Summary

How does MIRA Pharmaceuticals compare to Acumen Pharmaceuticals?

Summary

How does MIRA Pharmaceuticals compare to Protalix BioTherapeutics?

Summary

How does MIRA Pharmaceuticals compare to Molecular Partners?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MIRA Pharmaceuticals (MIRA) Competitors

MIRA vs. ENLV, GALT, ABOS, PLX, and MOLN

How does MIRA Pharmaceuticals compare to Enlivex Therapeutics?

Is MIRA or ENLV more profitable?

Does the media refer more to MIRA or ENLV?

Do analysts rate MIRA or ENLV?

Which has better earnings & valuation, MIRA or ENLV?

Do institutionals & insiders believe in MIRA or ENLV?

Which has more volatility & risk, MIRA or ENLV?

Summary

How does MIRA Pharmaceuticals compare to Galectin Therapeutics?

Do analysts prefer GALT or MIRA?

Which has more volatility and risk, GALT or MIRA?

Which has better earnings & valuation, GALT or MIRA?

Is GALT or MIRA more profitable?

Do insiders & institutionals have more ownership in GALT or MIRA?

Does the media favor GALT or MIRA?

Summary

How does MIRA Pharmaceuticals compare to Acumen Pharmaceuticals?

Which has preferable earnings & valuation, MIRA or ABOS?

Which has more volatility and risk, MIRA or ABOS?

Is MIRA or ABOS more profitable?

Does the media refer more to MIRA or ABOS?

Do analysts rate MIRA or ABOS?

Do insiders and institutionals hold more shares of MIRA or ABOS?

Summary

How does MIRA Pharmaceuticals compare to Protalix BioTherapeutics?

Which has more risk & volatility, PLX or MIRA?

Do analysts rate PLX or MIRA?

Which has higher earnings and valuation, PLX or MIRA?

Is PLX or MIRA more profitable?

Does the media favor PLX or MIRA?

Do institutionals & insiders hold more shares of PLX or MIRA?

Summary

How does MIRA Pharmaceuticals compare to Molecular Partners?

Which has more risk & volatility, MIRA or MOLN?

Which has stronger earnings & valuation, MIRA or MOLN?

Is MIRA or MOLN more profitable?

Does the media refer more to MIRA or MOLN?

Do institutionals and insiders have more ownership in MIRA or MOLN?

Do analysts prefer MIRA or MOLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIRA vs. The Competition

MIRA Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools